Clinical Research (03)

临床研究（03）

• 批准号: 9756776
• 负责人: Boris Pasche
• 金额: $ 0.83万
• 依托单位: WAKE FOREST UNIVERSITY HEALTH SCIENCES
• 依托单位国家: 美国
• 资助国家: 美国
• 起止时间: 至
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/9756776
• 关键词: Address; Baptist Church; Basic Science; Biochemistry; Brain; Breast; Breast Cancer Patient; Breast Cancer therapy; Cancer Biology; Cancer Center Support Grant; Cancer Control; Cancer Intervention; Cancer Survivor; Catchment Area; Clinical Research; Clinical Sciences; Clinical Trials; Collaborations; Communities; Community Clinical Oncology Program; Comprehensive Cancer Center; Cutaneous; Data; Development; Diagnostic; Disease; Doctor of Medicine; Elderly; Electromagnetic Fields; Electroporation; Erlotinib; Extramural Activities; Frequencies; Funding; Genitourinary system; Genomics; Geriatrics; Glioma; Goals; Gynecologic; Gynecology; Head Cancer; Head and neck structure; Hematologic Neoplasms; Impaired cognition; Incidence; Incubators; Intervention; Investigational Therapies; Late Effects; Lung; Magnetic Resonance Imaging; Malignant Neoplasms; Malignant neoplasm of brain; Malignant neoplasm of esophagus; Malignant neoplasm of liver; Malignant neoplasm of lung; Malignant neoplasm of pancreas; Metastatic malignant neoplasm to brain; Modality; NCI Center for Cancer Research; National Cancer Institute; Neck Cancer; Neoplasm Metastasis; Patients; Peer Review; Population; Population Sciences; Program Research Project Grants; Publications; Radiation therapy; Recurrence; Reporting; Research; Research Infrastructure; Research Personnel; Research Support; Resources; Science; Scientific Advances and Accomplishments; Scientist; Smoking; Solid Neoplasm; Supportive care; Toxic effect; Translating; Translations; Tumor Debulking; actionable mutation; base; cancer prevention; cancer site; cancer therapy; catalyst; chemotherapy; childhood sarcoma; clinical translation; donepezil; electric field; forest; gastrointestinal; health disparity; innovation; inter-institutional; intraperitoneal therapy; malignant breast neoplasm; melanoma; member; mitochondrial metabolism; novel; novel therapeutics; oncology program; oral mucositis; peritoneal cancer; phase 2 designs; precision medicine; programs; radiofrequency; response biomarker; symptom science; targeted agent; therapeutic development; treatment trial; tumor progression

CLINICAL RESEARCH PROGRAM Project Summary The major goal of the Clinical Research Program (CRP) of the Wake Forest Baptist Comprehensive Cancer Center (WFBCCC) is to serve as a hypothesis-driven incubator and catalyst for the clinical translation of novel therapeutic, diagnostic, and supportive care strategies. The goal of the CRP will be achieved through the following Specific Aims: (1) Translate advances in the understanding of cancer from the WFBCCC's basic sciences and population science Programs into novel therapeutic strategies with correlative biomarkers of response; (2) Promote the development and conduct of innovative clinical trials for rare or difficult to treat cancers and sites of metastasis; and (3) Enhance understanding in cancer-related symptom science, including leveraging the Wake Forest National Cancer Institute Community Oncology Program Research Base (WF NCORP RB; PI: Glenn Lesser, M.D.). CRP research is comprised of two themes within these aims: experimental therapeutics and addressing health disparities, with particular focus on cancers of high incidence in the WFBCCC catchment area. CRP is led by William Blackstock, M.D., with Dr. Lesser appointed as Program Co-Leader in August of 2015. The Program has 43 members from 17 different departments. Program members have $4.5M in peer-reviewed extramural funding (excluding training grants) of which 58.7% is from the NCI. Among the members' 513 publications, 23% were intra-programmatic, 14% were inter-programmatic, and 63% were inter-institutional during the 11/01/10 – 10/31/15 reporting period. The CRP has benefited from the ability to use the WF NCORP RB network as a platform for community-based clinical trials; in turn, the WF NCORP RB can translate the expertise of the CRP's clinician-scientists, strengthening each of these NCI- supported entities. Twelve Disease-Oriented Teams (DOTs) have been formalized within the WFBCCC research infrastructure to further enhance translation of WFBCCC science. Each DOT has a specific focus: brain, breast, geriatrics, gastrointestinal, genitourinary, gynecologic, head and neck, hematologic, lung, melanoma, pediatrics, and sarcoma. DOTs are comprised of basic scientists, population scientists, and clinicians, and serve as vehicles for robust interprogrammatic interactions leading to more innovative and comprehensive research portfolios. During the Data Table 3 reporting period of 07/01/14-06/30/15, 268 trials were open and 2,875 patients were accrued. Sixty-three percent of the trials were treatment trials, 15% were non-treatment interventions, and 21% were non-interventional studies. Twelve percent of treatment trials were investigator-initiated.

临床研究项目